

## Safe Orthopaedics: the European Patent Office confirms the validity of several key patents

- ▶ Decision by the European Patent Office following an opposition procedure
- ▶ Safe Orthopaedics holds a portfolio of nearly 100 patents
- ▶ Leading position enhanced by the strength of its industrial property
- ▶ Full support to the hospital teams engaged in the fight against the Covid-19 pandemic

---

Éragny-sur-Oise, France, March 23rd, 2020, 17h35 CET – Safe Orthopaedics (FR0013467123 – ALSAF), a company marketing innovative ready-to-use technologies (single-use implants and instruments) for spinal disease, delivering the safest treatment of spinal fractures, summarizes its strategy's progress on industrial property.

To this point, the company holds a portfolio of nearly 100 delivered patents, covering mainly Europe, United States, China, Canada and Japan. In 2019, several patents for its inventions have been delivered in the United States (instruments kit: US 10,219,845 and preloaded screw: US 9,837,817, innovative pedicle screw: US 10,357,286), in Canada (logistics and traceability of products: CA 2,837,817) and in China on an innovative implant (CN106102617B). Furthermore, Safe Orthopaedics keeps innovating and extending its instrumentation range, with the filing of new patents for spine reduction systems in 2019.

The strength of SAFE ORTHOPAEDICS' patents have just been confirmed by the European Patent Office (EPO) that has confirmed the validity of two patents (EP2854674 and EP2519179), against which the company Neo Medical had initiated an opposition procedure.

The potential offered by the development of ready-to-use and single-use instruments in spinal surgery has attracted new players and prompted the creation of numerous *start-up* companies, in Europe and in the United States.

On this high-growth market, Safe Orthopaedics claims its pioneer status, enhanced by the wide coverage and the strength of its patent portfolio. Safe Orthopaedics enjoys a leader status in terms of market shares and scope of its product range, covering the main indications for spinal fracture care.

SAFE ORTHOPAEDICS relies on a strategy of constant innovation and on an industrial property policy protecting its business development.

### *Covid-19 epidemic*

*"First and foremost, we wish to publicly express our warmest thanks and support to all of the doctors, surgeons, nurses and all of the members of the medical teams fighting against Covid-19. Although the care of infected patients is a priority, we are not forgetting the patient in need of emergency surgery for spinal fracture and we are reminded that our ready-to-use technologies are efficient solutions in this peak period in hospitals,"* says Pierre Dumouchel, Chairman and Chief Executive Officer *"While scrupulously respecting the containment measures, our sales and marketing teams remain 100% operational. The Safe Orthopaedics team can be reached by telephone, email and other connected means, and are coordinated with our logistics team in order to guarantee a 24/48h delivery of our ready-to-use sterile products on a European scale."*

### About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company, a pioneer of the design and marketing of innovative ready-to-use technologies (single-use implants and instruments) for spinal diseases, delivering the safest treatment of spinal fractures. The technologies include sterile implants and ready-to-use instruments available to the surgeon at anytime and anywhere, enabling minimally invasive approaches, reducing the risks of cross contamination and infection in the interest of the patient. Protected by 17 patent families, the SteriSpine™ Kits are CE marked, FDA and CFDA approved. Safe Orthopaedics, located at its headquarter close to Paris (95610 Eragny-Sur-Oise - France), has created a subsidiary in the UK, Germany and in the US, employing around 50 employees for a total sales of 4.7M€ in 2019.

For more information : [www.SafeOrthopaedics.com](http://www.SafeOrthopaedics.com)

### Contacts

#### Safe Orthopaedics

François-Henri Reynaud  
*Chief Financial Officer*  
Tél. : +33 (0)1 34 21 50 00  
[investors@safeorthopaedics.com](mailto:investors@safeorthopaedics.com)

#### Investor Relations

##### NewCap

Mathilde Bohin  
Tél.: +33 (0)1 44 71 94 94 / [SafeOrtho@newcap.eu](mailto:SafeOrtho@newcap.eu)

#### Press Relations

##### Ulysse Communication

Bruno Arabian / +33 (0)6 87 88 47 26 / [barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com)  
Nicolas Daniels / +33 (0)6 63 66 59 22 / [ndaniels@ulyse-communication.com](mailto:ndaniels@ulyse-communication.com)

